Invitation to press- and analyst conference
More News related to BVT
- Kiobrina(TM) shows positive phase II results in preterm infants
- Invitation to press- and analyst conference
- The creation of a new niche specialty pharmaceutical company focused on rare diseases - with strong cash flow generation and growth potential
- Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial
More News related to Press Releases
- Manufacturer of Zhu Zhu Pets Confirms Safety of Mr. Squiggles Toy and Offers Validation of Testing Protocol
- Giant Food Alerts Customers to Voluntary Recall of Del Monte College Inn No MSG Chicken Broth
- Stop & Shop Alerts Customers to Voluntary Recall of Del Monte College Inn No MSG Chicken Broth
- Raelian Iranian Leader Freed in Turkey
- Innovative Strategies Improve Outcomes and Reduce Life-Threatening Complications Associated With Stem Cell Transplants
STOCKHOLM, SWEDEN -- (MARKET WIRE) -- 11/05/09 -- Biovitrum AB (publ) will hold a press conference today to present the proposed combination with Swedish Orphan International AB.
Time: 11:00 (CET), today Thursday November 5, 2009 Venue: Carnegie's offices, Regeringsgatan 56 in Stockholm, Sweden
To follow the press conference over telephone, please use the following dial-in number: + 46 (0) 850 520 270.
Conference call at 16:00 (CET)
A conference call for investors and media in other time zones will be held in English this afternoon at 16:00 (CET). Presentation materials will be available on our web site: www.biovitrum.com, where it also will be possible to listen to the conference call afterwards. The dial-in number for the telephone conference is + 46 (0) 850 520 270.
Welcome!
Erik Kinnman, EVP Investor Relations Phone: +46 (0) 8 697 21 50, erik.kinnman@biovitrum.com
About Biovitrum
Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For more information please visit www.biovitrum.com
Invitation in PDF format: http://hugin.info/134557/R/1352888/327553.pdf
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
Related Categories
Press ReleasesStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
